Prof Dean Ho
Provost’s Chair Professor and Director, SINAPSE, National University of Singapore
Prof Dean Ho is currently Provost’s Chair Professor of Biomedical Engineering and Pharmacology, and Director of the Singapore Institute for Neurotechnology (SINAPSE) at the National University of Singapore.
Prof Ho and collaborators successfully developed and validated CURATE.AI, a powerful artificial intelligence technology platform based on the field of Phenotypic Personalized Medicine (PPM) to optimize clinical efficacy and safety for several combination therapy indications. He co-led the first in-human trial to personalize and optimize combination therapy for the entire duration of care, an unprecedented achievement. Specifically, his team partnered with leading surgeons to dynamically administer immunosuppressive therapies to prevent liver transplant rejection using CURATE.AI. CURATE.AI-treated patients dramatically outperformed control arm patients across every metric of comparison and were discharged nearly one month earlier compared to control patients (Science Translational Medicine, 2016). He also pioneered the development of nanodiamond platforms for the marked enhancement of efficacy and safety of drug delivery and imaging (Science Translational Medicine, 2011, 2013). Recently, Prof Ho initiated a first in-human clinical trial to validate a nanodiamond-biomaterial device for wound healing applications. Currently, Prof Ho is co-leading multiple oncologic combination therapy studies to dynamically modulate multi-drug regimens with CURATE.AI. These trials have resulted in completely halted disease progression and durable patient responses that far outperformed standard of care approaches.
Prof Ho has appeared on the National Geographic Channel Program “Known Universe” to discuss his discoveries in nanodiamond drug delivery and imaging. His discoveries have been featured on CNN, The Economist, Forbes, Washington Post, NPR and other international news outlets. Prof Ho has served as the President of the Board of Directors of the Society for Laboratory Automation and Screening (SLAS), a 26,000+ member global drug development organization comprised of senior executives from the pharmaceutical and medical device sectors, as well as academic visionaries.
Prof Ho was recently named a Fulbright Scholar. He is a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and Society for Laboratory Automation and Screening. He is also a recipient of the NSF CAREER Award, Wallace H. Coulter Foundation Translational Research Award, V Foundation for Cancer Research V Scholar Award, IADR William J. Gies Award, IADR Young Investigator Award, and Distinguished Young Alumnus award of the UCLA School of Engineering. Prof Ho is a co-founder of KYAN Therapeutics, and has previously advised venture funds and companies and in the areas of AI, digital medicine, and nanomedicine, among others.